Topic:

R&D

Latest Headlines

Latest Headlines

South Korea targets medical device industry as its latest growth engine

Business Korea reported that the government has a goal for its med tech industry to export more than $12.5 billion worth of goods, hire 130,000 people and have a 3.8% global market share by 2020.

Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running

Cancer diagnostics wunderkind Foundation Medicine has revealed plans to raise as much as $150 million in a secondary offering to fuel domestic and international expansion and the development of new products to keep the growth engine running.

Boehringer's stumble is InterMune's gain in lung drug race

InterMune watched its shares jump more than 15% after Boehringer Ingelheim posted some mixed results for its rival idiopathic pulmonary fibrosis treatment, all while the biotech has nearly tripled in value over the past 30 days.

Harvard team fingers missing protein as a key to Alzheimer's

The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly.

Pfizer snags a 'breakthrough' tag for its meningitis vaccine in a race with Novartis

Pfizer picked up the FDA's breakthrough therapy designation for an in-development vaccine against meningococcal disease, a common cause of meningitis, lighting the path for an accelerated approval as the drugmaker looks to expand its vaccine portfolio beyond the blockbuster Prevnar 13.

Geron sinks as liver risks plague another imetelstat trial

A week after the FDA put a halt to Geron's in-house studies of the cancer drug imetelstat over toxicity concerns, the agency stepped in on a Mayo Clinic-run trial of the same treatment, citing familiar dangers and imposing a partial clinical hold.

Cancer gamification project analyzes 1.5M chromosomes in one month

Nonprofit Cancer Research UK is developing a good track record in gamification. In the 18 months since it introduced "Cell Slider," citizen scientists have analyzed more than two million images of tumor samples, and it is now reporting strong uptake of its new mobile game.

Imaging tech developer NinePoint nails a $34M Series B from Corning, Third Rock and Prospect

Corning is the lead investor in NinePoint Medical's newly nailed-down $34 million Series B round. The 2012 Fierce 15 winner and developer of a cutting-edge organ imaging system also convinced founding investors Third Rock Ventures and Prospect Venture Partners to take part in the company's latest financing.

Circassia begins trading in London following successful IPO

The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.

MedImmune inks licensing deal with Bioasis for brain delivery platform

AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.